Deal Highlights
Deal Highlights
Deal Highlights
01
Cullinan Oncology Secures $712 Million Deal with Genrix for a BCMA and CD3 Bispecific T Cell Engager
Cullinan Oncology Secures $712 Million Deal with Genrix for a BCMA and CD3 Bispecific T Cell Engager
Cullinan Oncology Secures $712 Million Deal with Genrix for a BCMA and CD3 Bispecific T Cell Engager
02
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
03
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics.
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics.
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics.
Legal
© 2025 by Conexus Bio.
Legal
© 2025 by Conexus Bio.
Legal
© 2025 by Conexus Bio.